Drug updated on 5/17/2024
Dosage Form | Capsule (oral; 25 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
- Indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Midostaurin (Rydapt) is used for treating adults with newly identified acute myeloid leukemia (AML) that is FLT3 mutation positive, as well as for aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or mast cell leukemia.
- Three studies were analyzed to gather information about this medication.
- In comparison to other tyrosine kinase inhibitors, midostaurin has demonstrated significant efficacy in lowering relapse rates by 65% and enhancing overall survival rates among AML patients, particularly those with FLT3 mutations.
- Although effective, there have been significant instances of grade 3 or higher adverse events associated with midostaurin; nonetheless, the advantages may surpass these risks since the incidence of serious adverse events was relatively low.
- Relative to other therapies such as tyrosine kinase inhibitors and hypomethylating agents used in maintenance therapy post-transplantation for AML, midostaurin's safety profile was found to be comparable in terms of grade 3/4 infections and graft versus host disease.
- Research is ongoing, particularly concerning older AML patients, indicating a need for more comprehensive data on how different demographics may react to FLT3 inhibitors like midostaurin.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Rydapt (Midostaurin) Prescribing Information. | 2023 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Infectious complications of targeted drugs and biotherapies in acute leukemia. clinical practice guidelines by the european conference on infections in leukemia (ECIL), a joint venture of the european group for blood and marrow transplantation (EBMT), the european organization for research and treatment of cancer (EORTC), the international immunocompromised host society (ICHS) and the european leukemia net (ELN). | 2022 | Leukemia |
Treatment of advanced systemic mastocytosis with midostaurin: practical guidance for optimal therapy and management. | 2022 | Mediterranean Journal of Hematology and Infectious Diseases |
Acute myeloid leukemia. | 2019 | Alberta Health Services |
Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. | 2019 | Journal of the National Comprehensive Cancer Network |